Autoimmune Programs

About Kymera Therapeutics

Kymera Therapeutics is advancing a robust pipeline of PROTAC degraders targeting transcription factors, scaffolding proteins, and other previously undruggable proteins across oncology, immunology, and other therapeutic areas. The company has built a proprietary platform combining computational chemistry, structural biology, and proteomics to design selective protein degraders. With multiple programs in clinical development and strategic partnerships with leading pharmaceutical companies, Kymera is positioned as a leader in the emerging protein degradation field.

Therapeutic Areas